Skip to main content

Table 4 Univariate and multivariate analysis for DFS

From: Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy

Parameters

Univariate analysis

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

Age (≤ 49 vs. > 49)

1.08 (0.79–1.48)

0.638

  

Position (left vs. right)

0.92 (0.66–1.27)

0.602

  

BMI (< 24 vs. ≥ 24)

1.3 (0.94–1.79)

0.109

  

Height (≤ 1.6 vs. > 1.6)

0.93 (0.67–1.28)

0.648

  

Weight (≤ 61.5 vs. > 61.5)

1.29 (0.93–1.77)

0.123

  

Menopause (no vs. yes)

1.22 (0.89–1.68)

0.218

  

Preneoadjuvant chemotherapy hematological parameters

 mSIS (high risk vs. low risk)

0.72 (0.50–1.04)

0.078

  

 SIS (high risk vs. low risk)

1.10 (0.75–1.60)

0.629

  

 NLR (≤ 2.24 vs. > 2.24)

1.39 (1–1.94)

0.052

  

 LMR (≤ 2.96 vs. > 2.96)

0.6 (0.38–0.95)

0.028

0.57 (0.36–0.89)

0.0142

 Lymphocyte (≤ 1.96 vs. > 1.96)

0.97 (0.7–1.33)

0.834

  

 Neutrophil (≤ 3.76 vs. > 3.76)

1 (0.73–1.37)

0.992

  

 Monocyte (≤ 0.41 vs. > 0.41)

0.91 (0.66–1.25)

0.557

  

 Hemoglobin (≤ 135.4 vs. > 135.4)

0.66 (0.48–0.91)

0.012

0.78 (0.55–1.10)

0.1550

 Platelet (≤ 242 vs. > 242)

0.98 (0.71–1.35)

0.907

  

 Albumin (≤ 46.3 vs. > 46.3)

1.2 (0.84–1.7)

0.32

  

 Globulin (≤ 30 vs. > 30)

1 (0.73–1.38)

1

  

 Clinical T stage (1 vs. 2)

0.82 (0.51–1.33)

0.417

  

 Clinical T stage (1 vs. 3)

1.11 (0.64–1.95)

0.707

  

 Clinical T stage (1 vs. 4)

2.39 (0.81–7)

0.113

  

 Clinical N stage (0 vs. 1)

2.48 (0.83–7.38)

0.102

  

 Clinical N stage (0 vs. 2)

1.75 (0.64–4.78)

0.273

  

 Clinical N stage (0 vs. 3)

2.5 (0.9–6.96)

0.08

  

 Clinical TNM stage (I + II vs. III)

1 (0.62–1.62)

0.994

  

 Subtype (luminal A vs. B)

1.23 (0.73–2.06)

0.438

  

 Subtype (luminal A vs. HER-2 OE)

1.04 (0.58–1.84)

0.904

  

 Subtype (luminal A vs. TNBC)

1.1 (0.61–1.98)

0.761

  

 ER (negative vs. positive)

1.05 (0.76–1.45)

0.751

  

 PR (negative vs. positive)

1 (0.73–1.38)

0.981

  

 HER-2 (negative vs. low expression)

0.95 (0.64–1.4)

0.788

  

 HER-2 (negative vs. positive)

0.85 (0.58–1.24)

0.396

  

 Ki-67 (≤ 14% vs. > 14%)

0.98 (0.7–1.37)

0.912

  

 P53 (negative vs. positive)

0.86 (0.6–1.23)

0.409

  

Post neoadjuvant chemotherapy hematological parameters

 Lymphocyte (≤ 1.54 vs. > 1.54)

0.94 (0.68–1.29)

0.699

  

 Neutrophil (≤ 3.75 vs. > 3.75)

1.11 (0.81–1.53)

0.519

  

 Monocyte (≤ 0.53 vs. > 0.53)

0.82 (0.6–1.14)

0.238

  

 Hemoglobin (≤ 117 vs. > 117)

0.69 (0.5–0.95)

0.025

0.75 (0.53–1.06)

0.0982

 Platelet (≤ 271 vs. > 271)

1.07 (0.78–1.47)

0.672

  

 Albumin (≤ 46.3 vs. > 46.3)

0.96 (0.62–1.49)

0.855

  

 Globulin (≤ 28 vs. > 28)

0.82 (0.6–1.14)

0.239

  

 Cycle (< 4 vs. ≥ 4)

0.93 (0.59–1.46)

0.746

  

 pCR (no vs. yes)

0.44 (0.27–0.73)

0.001

0.43 (0.26–0.72)

0.0013